Pulsed and continuous wave doppler echocardiographic assessment of valvular regurgitation in normal subjects

Berger, Marvin; Hecht, Susan R.; Tosh, Andrew Van; Lingam, Umadevi

doi:10.1016/0735-1097(89)90345-8

Cited by 72 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Available literature has addressed the prevalence of valvular heart disease among a young, normal population and among older patients with and without systemic hypertension (6)(7)(8)(9)(10)(11)(12)14,15). The prevalence of significant valvular heart disease among middle-aged obese patients, representative of those referred for weight loss therapy, has been noted recently to range from 1.3% (4) to 4.5% (5).…”

Section: Background Prevalence Of Valve Diseasementioning

confidence: 99%

Absence of Cardiac Valve Dysfunction in Obese Patients Treated with Sibutramine

Bach

Rissanen²,

Mendel³

et al. 1999

Obesity Research

View full text Add to dashboard Cite

Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes Res. 1999;7:363-369. Objective: Serotonin-releasing agents prescribed as weightloss medications have been implicated as a cause of acquired aortic and mitral valve abnormalities. Sibutramine hydrochloride (MERIDIAB) is a serotonin and norepinephrine reuptake inhibitor with proven efficacy of weight reduction. The purpose of this study was to determine the incidence of cardiac valve disease in sibutraminetreated patients. Research Methods and Procedures: Obese patients with type 2 diabetes mellitus enrolled in an ongoing doubleblind, placebo-controlled, parallel-arm, 12-month study of sibutramine (followed by a 12-month open label extension) underwent transthoracic echocardiographic imaging and color Doppler interrogation for assessment of cardiac valve anatomy and function. Results: A total of 210 patients were evaluated. Of these, 133 were receiving sibutramine (72 in the double-blind period), and 77 were receiving placebo. The mean 2 Standard Deviation age was 5429 years, and the mean duration of treatment was 229+117 days (approximately 7.6 months). The prevalence of left-sided cardiac valve dysfunction was low and similar for the two treatment groups (sibutra- mine 31133, or 2.3%; placebo 2/77, or 2.6%). All five cases were cases of aortic insufficiency; four were mild, one was severe (in a placebo patient). All three sibutramine cases were patients over age 50; two had a history of systemic hypertension. Conclusion:The prevalence of left-sided cardiac valve dysfunction was not higher than background in obese patients treated with sibutramine for an average of 7.6 months.

show abstract

Section: Background Prevalence Of Valve Diseasementioning

confidence: 99%

Absence of Cardiac Valve Dysfunction in Obese Patients Treated with Sibutramine

Bach

Rissanen²,

Mendel³

et al. 1999

Obesity Research

View full text Add to dashboard Cite

show abstract

“…Their PWD and CWD results yielded a mean peak velocity of 0.9 m/sec, which was considered to be physiological (or trivial) as it was far below the generally accepted lower limit of about 4.5 m/sec peak velocity (Kienle and Thomas, 2002). In human patients, Berger et al (1989) concluded that a jet with a peak velocity of more than 4.0 m/sec may indicate abnormal mitral regurgitation. Table 2 Occurrence of mitral valve insufficiency (MVI) in clinically healthy dogs of various breeds Doppler echocardiography is considered to be the proper tool of diagnosing MVI and estimating its grade semi-quantitatively as has been done in this study and reported earlier (Pedersen et al, 1999a;Muzzi et al, 2003;Szilvási et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Occurrence of mitral valve insufficiency in clinically healthy Beagle dogs

Vörös

Szilvási

Manczur

et al. 2015

Acta Veterinaria Hungarica

View full text Add to dashboard Cite

Chronic degenerative valve disease (CDVD) is the most common cardiac disease in dogs, usually resulting in mitral valve insufficiency (MVI). The goal of this study was to investigate the occurrence of MVI in clinically healthy Beagle populations. A total of 79 adult healthy Beagles (41 females and 38 males; age: 5.6 ± 2.7 years, range 1.4 to 11.7 years) were examined. The diagnosis of MVI was based on the detection of a systolic murmur heard above the mitral valve, and was confirmed by colour flow Doppler (CFD) echocardiography. Systolic mitral valve murmurs were detected in 20/79 dogs (25.3%), of them 11 males and 9 females with no statistically significant gender difference (P = 0.6059). The strength of the murmur on the semi-quantitative 0/6 scale yielded intensity grade 1/6 in 10 dogs, grade 2/6 in 4 dogs, and grade 3/6 in 6 dogs. Mild to moderate MVI was detected by CFD in all these 20 dogs with systolic murmurs. Of them, 17 dogs had mild and 3 demonstrated moderate MVI, showing 10-30% and 30-50% regurgitant jets compared to the size of the left atrium, respectively. The age of dogs with MVI was 7.1 ± 2.3 years, which was significantly different from that of dogs without MVI (5.1 ± 2.7 years, P = 0.0029). No significant differences in body weight (P = 0.1724) were found between dogs with MVI (13.8 ± 2.8 kg) and those without MVI (12.8 ± 3.0 kg). Mitral valve disease causing MVI is relatively common in Beagle dogs, just like in other small breed dogs reported in the literature.

show abstract

“…Most of the cases of regurgitation are so mild that they cannot be heard as heart murmurs. It was well known that mild valvular regurgitation can be detected frequently in normal subjects using Doppler echocardiography (Kostucki et al 1986;Akasaka et al 1987;Berger et al 1989), so one can not neglect the possibility that some of the mild valvular regurgitation which was noted in the acute phase of Kawasaki syndrome have included "physiological" valvular regurgitation.…”

Section: Discussionmentioning

confidence: 99%